Knake S, Gruener J, Hattemer K, Klein K M, Bauer S, Oertel W H, Hamer H M, Rosenow F
Epilepsy Centre Marburg, Department of Neurology, Philipps-University Marburg, Rudolf-Bultmann-Str 8, 35033 Marburg, Germany.
J Neurol Neurosurg Psychiatry. 2008 May;79(5):588-9. doi: 10.1136/jnnp.2007.130260. Epub 2007 Sep 26.
In 2006, levetiracetam was approved as the first of the newer anticonvulsive drugs as an intravenous formulation (ivLEV) for patients with epileptic seizures who are unable to take oral medication. We report our experience with the use of ivLEV for the treatment of 18 episodes of benzodiazepine refractory focal status epilepticus (SE) in 16 patients, including four patients with secondary generalised SE. SE was controlled in all patients by the given combination of drugs; application of further antiepileptic medications after ivLEV was necessary in two episodes. No severe side effects occurred. Our data suggest that ivLEV may be an alternative for the treatment of SE in the future, even in patients that did not respond to benzodiazepines. A large prospective, randomised, controlled study is warranted to investigate the efficacy and safety of ivLEV for the treatment of SE.
2006年，左乙拉西坦作为新型抗惊厥药物中的首个品种被批准用于无法口服药物的癫痫发作患者的静脉制剂（ivLEV）。我们报告了使用ivLEV治疗16例患者的18次苯二氮䓬难治性局灶性癫痫持续状态（SE）发作的经验，其中包括4例继发性全面性SE患者。通过给定的药物组合，所有患者的SE均得到控制；在2次发作中，ivLEV后需要应用进一步的抗癫痫药物。未发生严重副作用。我们的数据表明，即使在对苯二氮䓬无反应的患者中，ivLEV将来也可能是治疗SE的一种选择。有必要进行一项大型前瞻性、随机、对照研究，以调查ivLEV治疗SE的疗效和安全性。
